April 2026- Brenntag, the global market leader in chemicals and ingredients distribution, unveiled BYPHAR yesterday in an online live press event.

BYPHAR is Brenntag’s new specialized biopharma brand, designed to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing. BYPHAR unifies Brenntag’s high‑quality raw materials, advanced facilities, and value‑added services into a comprehensive, regulatory‑ready portfolio supporting customers from early development through to commercial production.

BYPHAR is Brenntag’s solution specifically designed for use by Biopharma companies, helping their manufacturing process to shift from transactional supplier relationships towards a holistic, curated, compliant portfolio, streamlining complexity, accelerate timelines, and ultimately help bring more effective therapies to patients faster

BYPHAR provides a dependable gateway into highly regulated markets. The portfolio is backed by Brenntag’s global distribution network, long‑standing industry trust, and deep technical expertise ensuring secure supply, consistent documentation, and full regulatory compliance.

Click here to join our WhatsApp channel here

BYPHAR is engineered to support innovators, emerging biotech companies, CDMOs, vaccine manufacturers, biosimilar producers, and diagnostic companies across a wide range of manufacturing processes, including mAbs, Recombinant proteins, Cell & gene therapies, Vaccines, Nucleic acid–based production (mammalian or microbial), ADC manufacturing.

Gearoid O’Rourke, Senior Director Biopharma, Brenntag Pharma, states:“BYPHAR represents a major step forward in how we support our biopharma customers. By combining high‑quality raw materials and flexibility with global supply reliability and deep regulatory expertise, we are helping customers accelerate development and ensure the highest standards of all manufacturing stages.”

Also read: Zambia launches STEPS Survey on Noncommunicable Diseases